Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps

2 Oct 2017

Abstract excerpt

The introduction of a new Group A meningococcal conjugate vaccine, MenAfriVacR, has been a important public health success. Group A meningococcal meningitis has disappeared in all countries where the new Men A conjugate vaccine has been used at public health scale. However, continued control of Group A disease in sub-Saharan Africa will require that community immunity against Group A meningococci be maintained....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Pneumonia and Respiratory Infections
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28968148
DOI: 10.1080/21645515.2017.1378841

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next stepsPMID 28968148Read ↗

Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine.Semantic proximity Read ↗

Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine.Semantic proximity Read ↗

Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccinationSemantic proximity Read ↗

The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.Semantic proximity Read ↗

Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine.Semantic proximity Read ↗

A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)Semantic proximity Read ↗

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in AfricansSemantic proximity Read ↗

A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccineSemantic proximity Read ↗

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solutionSemantic proximity Read ↗

Meningococcal serogroup B vaccines: will they live up to expectations?Semantic proximity Read ↗

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?Semantic proximity Read ↗

Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian ToddlersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.